- About Us
- Nano-Social Network
- Nano Consulting
- My Account
June 29th, 2010
Venture capitalists and their limited partners have long bemoaned lackluster returns and the lengthening time until exits for portfolio companies. Publicly held venture firm Harris & Harris Group has gotten tired of waiting, and said it plans to invest more in public companies in a bid to make faster returns.
Since 2002, Harris & Harris has focused on backing companies with products based on nanotechnology or microsystems. Its private-company portfolio includes Mersana Therapeutics Inc., which develops cancer therapies based on its biodegradable polymer technology, and Solazyme Inc., which uses algae to produce clean fuels, chemicals, foods and health-science products.
|Related News Press|
News and information
New low-cost technique converts bulk alloys to oxide nanowires January 24th, 2017
Arrowhead Provides Response to New Minority Shareholder Announcement January 7th, 2017
Harris & Harris Group Announces a Proposed Strategic Restructuring December 20th, 2016
Arrowhead Pharmaceuticals to Webcast Fiscal 2016 Year End Results December 7th, 2016
Nanometrics Reports Second Quarter 2016 Financial Results July 26th, 2016